Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CDT Equity Inc. (NASDAQ: CDT) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on CDT’s corporate actions, financial reporting, governance decisions, and strategic developments as it operates as a data-driven biopharmaceutical development company.
CDT’s current reports on Form 8-K include items such as the approval and implementation of reverse stock splits, amendments to its certificate of incorporation, and the formal change of its corporate name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Filings also describe stockholder approvals related to the company’s stock incentive plan, the authorization of additional shares for equity awards, and matters voted on at annual and special meetings.
Other 8-K filings address topics like non-reliance on previously issued interim financial statements and planned restatements. For example, CDT has reported on the reclassification of certain milestone payments to Sarborg Limited from research and development expense to an acquired diagnostic asset, explaining how this affects its condensed consolidated financial statements. These disclosures help readers understand how the company applies accounting standards to its AI and diagnostic-related agreements.
Proxy materials, such as definitive proxy statements on Schedule 14A, provide further insight into CDT’s governance structure, director elections, auditor ratification, and proposals to amend stock plans. They also outline voting requirements, quorum definitions, and procedural details for virtual annual meetings.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, making it easier to interpret complex sections of 10-Ks, 10-Qs, 8-Ks, and proxy statements. Real-time updates from EDGAR ensure that new CDT filings, including any Form 4 insider transaction reports or future registration statements, are quickly reflected. This allows investors and researchers to review CDT’s regulatory history, corporate actions, and reporting practices in a structured, accessible format.
CDT Equity Inc. filed a Form S-8 to register an additional 2,000,000 shares of common stock for issuance under its Amended and Restated 2023 Stock Incentive Plan. The filing states the company changed its name to CDT Equity Inc. and effected 1-for-100 and 1-for-15 reverse stock splits; all share numbers reflect those splits. Prior registration statements had registered 7,665, 2,460 and 4,616 shares respectively. The filing incorporates recent SEC reports by reference.
CDT Equity Inc. completed a corporate rebranding, changing its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. and amending its bylaws to reflect the Name Change. The company confirmed its common stock will continue to trade on The Nasdaq Capital Market under the ticker CDT, and stated the CUSIP for the common stock will not change.
At its annual meeting, stockholders approved an amendment and restatement of the 2023 Stock Incentive Plan to authorize an additional 2,000,000 shares for awards. Stockholders also ratified CBIZ CPAs P.C. as the independent auditor and elected five director nominees. The board appointed James Bligh, a co-founder and interim CFO, as the company’s permanent Chief Financial Officer; he will remain a member of the board and his compensation remains as disclosed in the company’s proxy.